Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist

• US 7,252,822 B2
• Filed: 10/08/2003
• Issued: 08/07/2007
• Est. Priority Date: 10/08/2002
• Status: Active Grant

• Current Assignee: Rinat Neuroscience Corp. (Pfizer Inc.)
• Original Assignee: Rinat Neuroscience Corp. (Pfizer Inc.)
• Inventors: Vergara, German J., Shelton, David L.
• Primary Examiner(s): Saoud; Christine J.
• Assistant Examiner(s): LOCKARD, JON MCCLELLAND
• Application Number:
  US10/682,331
• Publication Number:
  US 20040228862A1
• Time in Patent Office: 1,399 Days
• Field of Search: None
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

The invention features methods and compositions for preventing or treating pain resulting from surgery or an incision by administering an antagonist of nerve growth factor (NGF). The NGF antagonist may be an anti-NGF (such as anti-hNGF) antibody that is capable of binding hNGF.

Claims

1. A method for treating post-surgical pain in a human subject comprising administering to the subject in need of such treatment an effective amount of an antagonist of nerve growth factor (NGF), whereby the post-surgical pain in the subject is treated, and wherein the NGF antagonist is other than TrkA immunoadhesin.

2. The method of claim 1, wherein the post-surgical pain comprises resting pain, and wherein the resting pain is ameliorated.

3. The method of claim 1, wherein the post-surgical pain comprises mechanically-induced pain, and wherein the mechanically-induced pain is ameliorated.

4. The method of claim 1, further wherein the NGF antagonist is other than an anti-NGF antibody.

5. The method of claim 1, wherein the NGF antagonist is a kinase inhibitor capable of inhibiting downstream kinase signaling associated with NGF receptor activity.

6. The method of claim 5, wherein the kinase inhibitor is K252a.

7. The method of claim 1, wherein the post-surgical pain comprises resting pain and mechanically-induced pain, and wherein the resting pain and mechanically-induced pain are ameliorated.

8. The method of claim 1, wherein the post-surgical pain comprises thermally-induced pain, and wherein the thermally-induced pain is ameliorated.

9. The method of claim 1, wherein the post-surgical pain comprises resting pain, mechanically-induced pain, and thermally-induced pain, and wherein the resting pain, mechanically-induced pain, and thermally-induced pain are ameliorated.

10. The method of claim 1, wherein wound healing is not significantly inhibited.